Loading...
•
Mar 31, 2021
Beam Therapeutics Q1 2021 Earnings Report
Beam Therapeutics reported first quarter 2021 financial results and presented LNP formulation data at ASGCT.
Key Takeaways
Beam Therapeutics reported a net loss of $201.6 million, or $3.35 per share, for the first quarter of 2021. The company's cash, cash equivalents, and marketable securities were $503.5 million as of March 31, 2021. Beam is on track to submit its first Investigational New Drug (IND) application for BEAM-101 in the second half of 2021.
Demonstrated in vivo editing in liver cells of non-human primates up to 52% using Beam’s novel LNP-mRNA formulation.
Company is on-track to submit First IND for BEAM-101 in the Second Half of 2021.
Presented data at ASGCT on proprietary lipid nanoparticle (LNP) formulation showing efficient in vivo base editing in hepatocytes of non-human primates (NHPs).
Reported development of a proprietary LNP formulation for non-viral in vivo delivery to the liver at ASGCT.
Revenue by Segment
Forward Guidance
Beam is on-track with its plans to submit its first Investigational New Drug (IND) application for BEAM-101 and initiate IND-enabling studies for BEAM-102 and BEAM-201, as well as nominate its first development candidate from its liver portfolio.
Positive Outlook
- On track to submit IND for BEAM-101 in second half of 2021
- Initiating IND-enabling studies for BEAM-102
- Initiating IND-enabling studies for BEAM-201
- Nominating first development candidate from liver portfolio
- Advancing base editing platform and pipeline
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...